REG - Hikma Pharmaceutical - Holding(s) in Company <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

20/12/2016 11:05

RNS Number : 3666S
Hikma Pharmaceuticals Plc
20 December 2016
For filings with the FCA include the annex

For filings with issuer exclude the annex


TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi


1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:ii
Hikma Pharmaceuticals PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):
Newissued sharecapital affected existing holding percentage
3. Full name of person(s) subject to the
notification obligation:iii
Darhold Limited
4. Full name of shareholder(s)
(if different from 3.):iv
Darhold Limited
5. Date of the transaction and date on
which the threshold is crossed or
reached:v
19 December 2016
6. Date on which issuer notified:
19 December 2016
7. Threshold(s) that is/are crossed or
reached: vi, vii
25%
8. Notified details:
A: Voting rights attached to sharesviii, ix
Class/type of
shares

if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of voting rights x
Indirect
Direct xi
Indirect xii
Direct
Indirect
GB00B0LCW083
59,909,270
59,909,270
60,000,000
60,000,000
0
25.00%
0


B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
date xiii
Exercise/
Conversion Period xiv
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights






C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price
Expiration date xvii
Exercise/
Conversion period xviii
Number of voting rights instrument refers to
% of voting rights xix, xx




Nominal
Delta


Total (A+B+C)
Number of voting rights
Percentage of voting rights
60,000,000
25.00%
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi
N/A
Proxy Voting:
10. Name of the proxy holder:
N/A
11. Number of voting rights proxy holder will acquire:
0
12. Date on which proxy holder will acquirevoting rights:
N/A


13. Additional information:

14. Contact name:
Peter Speirs, Company Secretary of Hikma Pharmaceuticals PLC
15. Contact telephone number:
+44 207 399 2772

This information is provided by RNS
The company news service from the London Stock Exchange
  END
HOLURVRRNNAUUAA